Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Inoue, Takayuki  [Clear All Filters]
2023
Kaida K, Ikegame K, Inoue T, Maruyama S, Ishii S, Uchida N, Doki N, Eto T, Fukuda T, Katayama Y, et al. Peritransplant glucocorticoid haploidentical stem cell transplantation is a promising strategy for AML patients with high leukemic burden: Comparison with transplants using other donor types. Transplant Cell Ther. 2023.
2021
Inoue T, Koyama M, Kaida K, Ikegame K, Ensbey KS, Samson L, Takahashi S, Zhang P, Minnie SA, Maruyama S, et al. Peri-transplant glucocorticoids redistribute donor T-cells to the bone marrow and prevent relapse after haploidentical SCT. JCI Insight. 2021.
2020
Ikegame K, Kaida K, Fukunaga K, Osugi Y, Yoshihara K, Yoshihara S, Ishii S, Fujino S, Yamashita T, Mayumi A, et al. Allogeneic hematopoietic stem cell transplantation from a 2-HLA-haplotype-mismatched family donor for posttransplant relapse: a prospective phase I/II study. Bone Marrow Transplant. 2020.
2019
Tamaki H, Ikegame K, Yoshihara S, Kaida K, Yoshihara K, Inoue T, Kato R, Nakata J, Fujioka T, Soma T, et al. Low incidence of HHV-6 reactivation in haploidentical hematopoietic stem cell transplantation with corticosteroid as graft-versus-host disease prophylaxis compared with cord blood transplantation. Transpl Infect Dis. 2019:e13073.
2016
Ikegame K, Imai K, Yamashita M, Hoshino A, Kanegane H, Morio T, Kaida K, Inoue T, Soma T, Tamaki H, et al. Allogeneic stem cell transplantation for X-linked agammaglobulinemia using reduced intensity conditioning as a model of the reconstitution of humoral immunity. J Hematol Oncol. 2016;9(1):9.
2014
Kaida K, Ikegame K, Ikemoto J, Murata R, Irie R, Yoshihara S, Ishii S, Okada M, Inoue T, Tamaki H, et al. Soluble interleukin-2 receptor level on day 7 as a predictor of graft-versus-host disease after HLA-haploidentical stem cell transplantation using reduced-intensity conditioning. Int J Hematol. 2014.